As the vaccine race enters the homestretch, Pfizer and Moderna both announced that their mRNA vaccines was 95 percent effective in preventing COVID-19 during Phase 3 clinical trials. Emergency use authorization could be just weeks away. The National Academy of Sciences released an influential report about who gets vaccinated first while companies scale up vaccine production. The Academy makes a compelling case that prioritizing those with risky healthy conditions and risky, essential jobs is the surest way to mitigate death, serious disease, rising case counts and growing socioeconomic crises in vulnerable communities across the country.
